BAUSCH HEALTH COMPANIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.45 USD | -2.76% |
|
-2.09% | +5.36% |
| Apr. 22 | RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 | MT |
| Apr. 19 | Bausch Health's Issuer Credit Rating Upgraded by S&P | MT |
Chart calendar Bausch Health Companies Inc.
abf958b4a3b5c51.Todt9qnQSpsfDawX8lR5enNf1HBPIMehIgB_FZ2ssl0.dvM6lO6fAOxtR-RCuz0_PUcQrQp3FKv4VngRV-TW2zsZzgyj9qgI_mdInA~f968ad02ad61d9250b73a80d4e2cd55a
Upcoming events on Bausch Health Companies Inc.
Past events on Bausch Health Companies Inc.
| 2024-03-05 12:50 pm | TD Cowen Health Care Conference |
| 2024-02-22 08:00 am | Q4 2023 Earnings Call |
| 2024-02-22 07:24 am | Q4 2023 Earnings Release |
| 2023-11-02 08:00 am | Q3 2023 Earnings Call |
| 2023-11-02 07:00 am | Q3 2023 Earnings Release |
| 2023-08-03 08:00 am | Q2 2023 Earnings Call |
| 2023-08-03 07:00 am | Q2 2023 Earnings Release |
| 2023-07-06 | American Dental Hygienists Association Conference |
| 2023-06-24 03:00 am | European Association for the Study of the Liver Congress - Title: "Impact of rifaximin use post-disc |
| 2023-06-21 03:00 am | European Association for the Study of the Liver Congress - Serum Ammonia Levels |
| 2023-06-21 03:00 am | European Association for the Study of the Liver Congress - Rifaximin Plus Lactulose |
| 2023-05-16 09:00 am | Annual General Meeting |
| 2023-05-09 01:30 pm | Digestive Disease Week - Abstract Number #-3862445 |
| 2023-05-09 01:30 pm | Digestive Disease Week - Abstract Number #-3860993 |
| 2023-05-09 01:30 pm | Digestive Disease Week - Abstract Number #-3853017 |
| 2023-05-08 03:30 pm | Digestive Disease Week - Abstract Number #-3857579 |
| 2023-05-07 01:30 pm | Digestive Disease Week Meeting - Abstract Number #-3862864 |
| 2023-05-07 01:30 pm | Digestive Disease Week - Abstract Number #-3859401 |
| 2023-05-04 08:00 am | Q1 2023 Earnings Call |
| 2023-05-04 07:00 am | Q1 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 8 601 8 572 0.34% | 8 027 7 968 0.74% | 8 434 8 465 -0.37% | 8 124 8 063 0.75% | 8 757 8 647 1.27% | 9 393 |
|
EBITDA Million USD | Released Forecast Spread | 3 571 3 585 -0.38% | 3 294 3 257 1.13% | 3 472 3 426 1.33% | 3 022 3 017 0.18% | 3 014 3 005 0.3% | 3 253 |
|
EBIT Million USD | Released Forecast Spread | 3 226 3 304 -2.37% | 2 959 3 003 -1.46% | 2 951 3 118 -5.34% | 2 775 2 763 0.43% | 2 808 2 795 0.48% | 3 045 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -1 837 -423 -334.23% | -934 -577 -61.82% | -1 024 -1 010 -1.39% | -129 305 -142.3% | -390 -267 -46.31% | 314 |
|
Net income Million USD | Released Forecast Spread | -1 788 -333 -436.32% | -560 -529 -5.89% | -948 -1 003 5.52% | -225 188 -219.41% | -592 -478 -23.89% | 238 |
|
EPS USD | Released Forecast Spread | -5,08 -0,97 -421.56% | -1,58 -1,47 -7.48% | -2,64 -2,83 6.63% | -0,62 0,51 -221.57% | -1,62 -1,28 -26.89% | 0,66 |
| Announcement Date | 19/02/20 | 24/02/21 | 23/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2 196 2 207 -0.5% | 1 918 2 040 -5.96% | 1 967 2 044 -3.78% | 2 046 2 058 -0.6% | 2 193 2 136 2.69% | 1 944 1 945 -0.07% | 2 167 2 047 5.86% | 2 238 2 158 3.72% | 2 408 2 295 4.93% | 2 154 | 2 341 | 2 408 | 2 490 | 2 235 |
|
EBITDA Million USD | Released Forecast Spread | 909 880 3.32% | 732 817 -10.42% | 701 775 -9.56% | 766 776 -1.31% | 823 812 1.31% | 588 701 -16.08% | 727 705 3.13% | 830 809 2.62% | 869 850 2.23% | 720 | 793 | 837 | 869 | 792 |
|
EBIT Million USD | Released Forecast Spread | 773 797 -3.01% | 618 751 -17.68% | 587 728 -19.37% | 668 716 -6.76% | 771 764 0.96% | 494 633 -21.92% | 651 680 -4.32% | 747 666 12.14% | 812 798 1.72% | 708 | 754 | 784 | 792 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 21,0 186 -88.71% | -82,0 32,0 -356.25% | -129 -66,0 -95.45% | 439 177 147.68% | -357 245 -245.81% | -136 -42,0 -223.81% | 79,0 -23,0 443.48% | -326 119 -374.09% | -7,00 116 -106.01% | -14,4 | 63,9 | 112 | 148 | 71,7 |
|
Net income Million USD | Released Forecast Spread | 69,0 124 -44.35% | -69,0 -16,0 -331.25% | -145 -63,0 -130.16% | 399 122 225.97% | -410 176 -333.27% | -201 -87,0 -131.03% | 26,0 -31,8 181.77% | -378 49,6 -862.76% | -39,0 81,8 -147.67% | -97,0 | -10,0 | 54,0 | 94,0 | |
|
EPS USD | Released Forecast Spread | 0,19 0,11 72.73% | -0,19 0,06 -416.67% | -0,40 -0,10 -321.05% | 1,10 0,21 415.63% | -1,13 -0,01 -11200% | -0,55 -0,13 -340% | 0,07 -0,05 240% | -1,03 0,14 -835.71% | -0,11 0,24 -145.21% | -0,11 | 0,07 | 0,18 | 0,26 | 0,14 |
| Announcement Date | 23/02/22 | 10/05/22 | 09/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 22/02/24 | - | - | - | - | - |
More events
Past sector events for Bausch Health Companies Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BHC Stock
- Calendar Bausch Health Companies Inc.
